Hematologic Oncology

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

TERN-701 reduced BCR-ABL levels and produced molecular responses in relapsed/refractory chronic myeloid leukemia.

LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

Neil P. Shah, MD, PhD, highlights key recent changes to the CML NCCN guidelines and details anticipated data for 2025.

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia.

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.

The FDA has approved nilotinib tablets without mealtime restrictions for select patients with chronic myeloid leukemia.

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.